We develop frontier foundation models and wet-lab technologies that make complex biologics manufacturable. Our platform predicts and optimizes upstream bioprocess conditions, cell line behavior, and molecular developability. We aim to cut 3 to 6 months off manufacturing timelines and enable drugs that would otherwise be abandoned at the CMC stage. To maximize patient impact, we partner with biopharma and CDMOs. If successful, we could meaningfully expand the number of effective therapeutics that reach patients across oncology, immunology, and rare disease, including molecules that today's manufacturing platforms cannot support.

Abinitio Bio

Org chart

Teams

Offices

Abinitio Bio

Org chart

Teams

Offices

Related companies